Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that Mycobacterium avium paratuberculosis positive Relapsing
Remitting MS subjects will have a greater response to Interferon beta-1a therapy plus RHB-104
than from Interferon beta-1a alone.